Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

• Published in: BMC veterinary research Vol. 11; no. 1; p. 210
• Main Authors: Olivry, Thierry, DeBoer, Douglas J, Favrot, Claude, Jackson, Hilary A, Mueller, Ralf S, Nuttall, Tim, Prélaud, Pascal
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16-08-2015; BioMed Central
• Subjects: Acute Disease; Administration, Oral; Administration, Topical; Advertising executives; Animals; Anti-Infective Agents - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Atopic dermatitis; Baths - veterinary; Care and treatment; Chronic Disease; Correspondence; Dermatitis, Atopic - therapy; Dermatitis, Atopic - veterinary; Dermatologic Agents - therapeutic use; Dog Diseases - drug therapy; Dogs; Drug therapy; Drug Therapy, Combination - veterinary; Evidence-based medicine; Glucocorticoids - therapeutic use; Interferon; International Cooperation; Pharmaceutical industry; Practice Guidelines as Topic; Pruritus; Skin; Switzerland
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/s12917-015-0514-6

In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document.
The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD.
This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.